Fig. 5
From: Proteolysis-targeting chimeras (PROTACs) in cancer therapy
PROTACs targeting cancer immune evasion and inflammation. Cancer cells promote immune evasion and inflammation by reprogramming tumor microenvironment that involves BCR, TCR and JAK-STAT pathways. These components in cancer immune evasion and inflammation can be targeted by PROTACs (red arrow). Tumor-suppressor proteins are indicated in blue and oncogenic proteins are indicated in red. In the presented pathways, PROTACs have been developed targeting PD-L1 [215], BTK [216,217,218,219], STAT3 [57], HPK1 [220], IDO1 [221], ITK [161], JAK [222] and SHP2 [223]